Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Opening of the First Gustave Roussy-Branded Facility in Egypt
Named Gustave Roussy International Egypt, the opening of a cancer centre in Cairo, Egypt, marks the transformation of the Dar Al-Salam-Hermel Oncology Hospital under a brand licensing agreement with Gustave Roussy International, a subsidiary of Gustave Roussy.
Published on
Named Gustave Roussy International Egypt, the opening of a cancer centre in Cairo, Egypt, marks the transformation of the Dar Al-Salam-Hermel Oncology Hospital under a brand licensing agreement with Gustave Roussy International, a subsidiary of Gustave Roussy. The centre will eventually be equipped with 300 beds and will be capable of treating all types of adult cancers. Two new buildings will be constructed to strengthen and complete the existing infrastructure. This ambitious project, carried out in partnership with the Government of the Arab Republic of Egypt and Elevate P.E., aims to establish the centre as a hub of excellence in oncology for Egypt and the wider region.
On 7 April, a joint declaration confirming the commitment to collaboration was signed between the Arab Republic of Egypt and the French Republic in the presence of French President Emmanuel Macron, under the high patronage of President Abdel Fattah El-Sisi. The declaration was signed by Professor Khaled Abdel Ghaffar, Vice Prime Minister, Minister of Health and Population, and Professor Fabrice Barlesi, CEO of Gustave Roussy and representative of Gustave Roussy International.
The brand licensing agreement between Gustave Roussy International and Elevate P.E. was signed following this event, in the presence of Catherine Vautrin, French Minister for Labour, Health, Solidarity and Families, Éric Lombard, Minister for the Economy, Finance and Industrial and Digital Sovereignty, and Rania Al-Mashat, Egyptian Minister of Planning, Economic Development and International Cooperation, along with Professor Khaled Abdel Ghaffar.
Following these agreements, Gustave Roussy International Egypt welcomed its first patients on 8 April 2025. The cancer centre aims to become a regional reference by integrating cutting-edge technologies in radiotherapy, genomics, and innovative treatments. It is committed to providing patients with high-quality care, with a particular focus on those from the public sector, who are expected to make up 70% of its beneficiaries.
A structured training programme will enhance the skills of Egyptian healthcare professionals and ensure the lasting dissemination of oncology excellence standards. Doctors from Gustave Roussy will travel to Egypt for training and consultation missions, while their Egyptian counterparts will be hosted in France to attend master classes, particularly in chemotherapy.
Last news
-
Gustave Roussy at the ESMO 2026 Congress
The European Society for Medical Oncology (ESMO) is holding its annual congress from 23 to 27 October in Madrid, Spain. This major international event provides oncologists and researchers from around the world with an opportunity to present the latest findings from clinical studies aimed at improving cancer care and deepening our understanding of the disease. Once again, this year, physicians and researchers from Gustave Roussy have contributed to several dozen studies that will be presented during the five-day congress.
-
5 questions with Dr François-Xavier Danlos about therapeutic cancer vaccines
Therapeutic cancer vaccines are making significant progress in clinical development. The ESMO Congress, which begins on 23 October, will provide an opportunity to learn about new data on a therapeutic vaccine against melanoma. However, there are major differences between vaccines traditionally used to prevent disease and therapeutic cancer vaccines. Dr François-Xavier Danlos, a medical oncologist in Gustave Roussy’s Drug Development Department and a specialist in immunotherapy development, explains.
-
ADCs: Two Landmark Publications in Cancer Cell and Nature Medicine Showcase Gustave Roussy's Expertise
In less than two months, researchers and clinicians from Gustave Roussy have contributed to two major publications on Antibody-Drug Conjugates (ADCs) in Cancer Cell and Nature Medicine. Together, these papers provide both a comprehensive overview of current knowledge and a strategic vision to accelerate the development of the next generation of these innovative therapies.
-
Drug shortages: Gustave Roussy becomes the only Cancer Centre in France authorised to produce Special Hospital Preparations
The Clinical Pharmacy Department at Gustave Roussy has been authorised by the French Ministry of Health to manufacture Special Hospital Preparations (SHPs). Granted for a period of seven years, this accreditation enables the Institute’s hospital pharmacy to produce certain medicines in coordination with the French National Agency for the Safety of Medicines and Health Products (ANSM) and the Ministry of Health. Gustave Roussy is the only French Comprehensive Cancer Centre (CLCC) authorised to manufacture Special Hospital Preparations, alongside ten university hospitals.
